Renhua H. Guo

300 Guangzhou Road
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 24, 2026

Clinical characteristics and prognosis analysis of newly diagnosed multiple myeloma with t (4;14)

Clinical characteristics and prognosis analysis of newly diagnosed multiple myeloma with t (4;14)

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: April 16, 2026

Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI and the underlying mechanisms

Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI and the underlying mechanisms

Journal: Zhonghua yi xue za zhi

Published: February 11, 2026

Prognostic value of high-risk cytogenetic abnormalities inmultiple myeloma

Prognostic value of high-risk cytogenetic abnormalities inmultiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 03, 2025

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 09, 2025

Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.

Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.

Journal: Cancer science

Published: August 30, 2025

Long-term survival with adaptive dual-targeted therapy in an epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patient with mesenchymal-epithelial transition (MET) amplification guided by minimal residual disease (MRD) assessments: a case report and literature review.

Long-term survival with adaptive dual-targeted therapy in an epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patient with mesenchymal-epithelial transition (MET) amplification guided by minimal residual disease (MRD) assessments: a case report and literature review.

Journal: Translational lung cancer research

Published: July 22, 2025

TKI resistance related genes in LUAD predict patient prognosis and tumor immune microenvironment with LHX2 as a hub gene.

TKI resistance related genes in LUAD predict patient prognosis and tumor immune microenvironment with LHX2 as a hub gene.

Journal: Discover oncology

Published: July 15, 2025

Effect of SMARCA4 mutations on the outcomes of patients with advanced EGFR mutant lung adenocarcinoma

Effect of SMARCA4 mutations on the outcomes of patients with advanced EGFR mutant lung adenocarcinoma

Journal: Zhonghua yi xue za zhi

Published: January 26, 2025

Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.

Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 04, 2024

NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer.

NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer.

Journal: Molecular cancer

Published: October 09, 2024

Circular RNA circHSPA8 Aggravates Metastasis by Acting as a Competitive Inhibitor of miR-195-5p to Upregulate WNT3A Expression in Breast Cancer.

Circular RNA circHSPA8 Aggravates Metastasis by Acting as a Competitive Inhibitor of miR-195-5p to Upregulate WNT3A Expression in Breast Cancer.

Journal: Journal of cellular and molecular medicine

Published: August 22, 2024

Showing 1-12 of 105

Last Updated: 09/26/2026